Delcath Systems Inc (DCTH) - Total Liabilities

Latest as of December 2025: $12.41 Million USD

Based on the latest financial reports, Delcath Systems Inc (DCTH) has total liabilities worth $12.41 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Delcath Systems Inc (DCTH) cash flow conversion to assess how effectively this company generates cash.

Delcath Systems Inc - Total Liabilities Trend (1999–2025)

This chart illustrates how Delcath Systems Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Delcath Systems Inc's assets to evaluate the company's liquid asset resilience ratio.

Delcath Systems Inc Competitors by Total Liabilities

The table below lists competitors of Delcath Systems Inc ranked by their total liabilities.

Company Country Total Liabilities
LUBAWA SA
WAR:LBW
Poland zł151.17 Million
Fastighets AB Trianon (publ)
ST:TRIAN-B
Sweden Skr8.26 Billion
SEONGAN CO. Ltd
KO:011300
Korea ₩70.52 Billion
Mirbud SA
WAR:MRB
Poland zł1.50 Billion
Cahya Mata Sarawak Bhd
KLSE:2852
Malaysia RM801.52 Million
Bredband2 i Skandinavien AB
ST:BRE2
Sweden Skr754.39 Million
FuelCell Energy Inc
NASDAQ:FCEL
USA $201.00 Million
Aeris Resources Ltd
AU:AIS
Australia AU$257.43 Million

Liability Composition Analysis (1999–2025)

This chart breaks down Delcath Systems Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Delcath Systems Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.92 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Delcath Systems Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Delcath Systems Inc (1999–2025)

The table below shows the annual total liabilities of Delcath Systems Inc from 1999 to 2025.

Year Total Liabilities Change
2025-12-31 $12.41 Million +58.27%
2024-12-31 $7.84 Million -65.66%
2023-12-31 $22.84 Million -3.73%
2022-12-31 $23.72 Million +12.04%
2021-12-31 $21.17 Million +68.61%
2020-12-31 $12.56 Million -38.95%
2019-12-31 $20.57 Million -5.57%
2018-12-31 $21.78 Million +165.36%
2017-12-31 $8.21 Million -77.65%
2016-12-31 $36.73 Million +414.99%
2015-12-31 $7.13 Million +26.93%
2014-12-31 $5.62 Million -19.71%
2013-12-31 $7.00 Million -33.13%
2012-12-31 $10.46 Million +14.53%
2011-12-31 $9.14 Million -57.50%
2010-12-31 $21.50 Million +64.75%
2009-12-31 $13.05 Million +1032.89%
2008-12-31 $1.15 Million -31.33%
2007-12-31 $1.68 Million +150.20%
2006-12-31 $670.37K +103.10%
2005-12-31 $330.07K -41.54%
2004-12-31 $564.63K +117.00%
2003-12-31 $260.20K +48.54%
2002-12-31 $175.17K -0.52%
2001-12-31 $176.08K -82.89%
2000-12-31 $1.03 Million +835.38%
1999-12-31 $110.00K --

About Delcath Systems Inc

NASDAQ:DCTH USA Medical Devices
Market Cap
$375.26 Million
Market Cap Rank
#14500 Global
#3265 in USA
Share Price
$10.80
Change (1 day)
+4.05%
52-Week Range
$8.19 - $18.10
All Time High
$1000000.00
About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more